英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
khamal查看　khamal　在百度字典中的解释百度英翻中〔查看〕
khamal查看　khamal　在Google字典中的解释Google英翻中〔查看〕
khamal查看　khamal　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Merck Moves Forward in Bid To Bring First Oral PCSK9 . . . - BioSpace
    The Lipids study is expected to wrap up later this year, as per the BMO note, while the Outcomes trial has a primary completion date of November 2029 Merck did not detail its regulatory plans for the drug in Monday’s release but noted that if approved, enlicitide decanoate would become the first oral PCSK9 inhibitor on the market
  • Enlicitide chloride - Wikipedia
    Enlicitide chloride (INN; [1] previously known as MK-0616) is a macrocyclic peptide investigational drug that is being evaluated for the treatment of hypercholesterolaemia It is a PCSK9 inhibitor [2] Merck has launched a Phase 3 clinical trial to evaluate the efficacy and safety of MK-0616 in Adults With Hypercholesterolemia [3] [4]
  • Groundbreaking Drug Launches: Notable mentions - Market Movers of 2025
    Merck is expected to announce Phase III results this year for enlicitide decanoate, a promising first-in-class oral PCSK9 inhibitor with once-daily dosing This could improve cholesterol management for statin users and create a new revenue stream as Keytruda’s patent approaches expiration
  • MSD moves ahead in race to bring oral PCSK9 drug to market
    CORALreef AddOn is testing enlicitide against other oral therapies, including ezetimibe and bempedoic acid, as well as combination therapy in people with hypercholesterolaemia who are
  • Mercks potential cholesterol pill succeeds in late-stage studies
    Merck's non-statin cholesterol drug, enlicitide decanoate, is being tested for the treatment of hyperlipidemia, a condition that causes elevated buildup of fat in the blood vessels and can lead to heart attacks and strokes
  • Enlicitide Chloride – Application in Therapy and Current Clinical Research
    Enlicitide Chloride, also known as MK-0616, is an oral PCSK9 inhibitor currently being studied in clinical trials This article examines the ongoing research into this promising drug, focusing on its safety, tolerability, and effectiveness in various patient populations
  • Ozmosi | Enlicitide Drug Profile
    Enlicitide is an investigational, potentially first oral PCSK9 inhibitor designed to lower low density lipoprotein (LDL) cholesterol MK-0616 is a macrocyclic peptide that binds to PCSK9 and inhibits the interaction of PCSK9 with LDL receptors
  • MK-0616 Cardiovascular Outcomes Study - Merck Clinical Trials
    The primary objective is to evaluate the efficacy of enlicitide decanoate compared with placebo in increasing the time to the first occurrence of major adverse cardiovascular events (MACE) including coronary heart disease (CHD) death, ischemic stroke, myocardial infarction (MI), acute limb ischemia or major amputation, or urgent arterial
  • Merck Launches Oral PCSK9 Inhibitor for Cholesterol
    Merck has introduced ‘Enlicitide Decanoate,’ the first oral PCSK9 inhibitor for high cholesterol and heart disease Backed by promising phase III trials, this breakthrough treatment could reshape cardiovascular care by offering a convenient alternative to injectable therapies
  • Merck Announces Positive Topline Results From the First Two Phase 3 . . .
    RAHWAY, N J --(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the first two of three Phase 3 clinical trials evaluating the safety and efficacy of enlicitide decanoate, an investigational, oral proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor being evaluated for the treatment of adults with





中文字典-英文字典  2005-2009